This site is intended for UK healthcare professionals
Medscape UK Univadis Logo
Medscape UK Univadis Logo

Ocriplasmin intravitreal injection

Updated 2 Feb 2023 | Vitreomacular traction


Single use vial containing ocriplasmin in solution.

Ocriplasmin is a truncated form of human plasmin produced by recombinant DNA technology in a Pichia pastoris expression system.

Drugs List

  • JETREA 0.375mg/0.3ml solution for injection vial
  • ocriplasmin 375microgram/0.3ml solution for injection vial
  • Therapeutic Indications


    Treatment of vitreomacular traction



    Single dose of 0.125mg in 0.1ml of solution for injection administered by intravitreal injection to the affected eye.

    Treatment with this medication into the other eye is not recommended concurrently or within 7 days of the initial injection.

    Repeated administration in the same eye is not recommended.


    Only 0.1ml of the total 0.3ml in the vial should be administered. Discard any excess volume prior to injection.


    Children under 18 years
    Exudative age-related macular degeneration
    High myopia (> 8 dioptre spherical correction or axial length > 28mm)
    History of rhegmatogenous retinal detachment
    Intravitreous haemorrhage
    Ischaemic retinopathies
    Lens zonule instability
    Macular holes (> 400 microns)
    Ocular infection
    Periocular infection
    Proliferative diabetic retinopathy
    Recent ocular surgery
    Retinal blood vessel occlusion

    Precautions and Warnings

    Predisposition to uveitis
    Diabetic retinopathy
    Ocular trauma
    Severe intra-ocular inflammation

    Advise visual disturbances may affect ability to drive or operate machinery
    Treatment of second eye is not recommended within 7 days
    For single use only
    Repeated use is not recommended
    Treatment to be administered under the supervision of a specialist
    Monitor during the week following injection for signs of infection
    Monitor intra-ocular pressure post injection and manage appropriately
    Monitor visual acuity during and after treatment
    Advise patient to report any unexpected changes in eye symptoms immediately
    May affect the results of routine ophthalmological examinations

    Patients with an epiretinal membrane, or a vitreomacular adhesion with diameter larger than 1500 microns, may experience a reduced effect of ocriplasmin.

    May affect the results of routine ophthalmological examinations including full-field ERG, colour vision test (Roth 28-hue), optical coherence tomography (OCT) and ophthalmoscopy (foveal reflex). When using these tests for subsequent diagnosis or monitoring of other conditions, the effect of ocriplasmin should be considered.

    Pregnancy and Lactation


    Use ocriplasmin with caution during pregnancy.

    The manufacturer advises caution if ocriplasmin is used during pregnancy, and only when potential benefit outweighs risk. At the time of writing there is limited published information regarding the use of ocriplasmin during pregnancy. Potential risks are unknown. The systemic exposure of this medication is expected to be very low after intravitreal injection.


    Use ocriplasmin with caution during breastfeeding.

    The manufacturer advises caution if ocriplasmin is used when breastfeeding. The presence of ocriplasmin in human breast milk is unknown but due to its large molecular weight, transfer is not expected (Briggs, 2015). Effects on exposed infants are unknown.

    Side Effects

    Anterior chamber flare
    Anterior chamber inflammation
    Blindness (temporary)
    Blurred vision
    Cells in anterior chamber of eye
    Conjunctival haemorrhage
    Conjunctival hyperaemia
    Conjunctival irritation
    Conjunctival oedema
    Corneal abrasion
    Double vision
    Dry eyes
    Eyelid oedema
    Impaired vision
    Increased intra-ocular pressure
    Increased lacrimation
    Lens subluxation
    Macular abnormalities
    Macular degeneration
    Macular hole
    Macular oedema
    Night blindness
    Ocular discomfort
    Ocular hyperaemia
    Ocular inflammation
    Ocular irritation
    Ocular pain
    Ocular pruritus
    Optical coherence tomography (OCT) abnormal
    Pupillary disorder
    Reduced visual acuity
    Retinal degeneration
    Retinal detachment
    Retinal disturbances
    Retinal haemorrhage
    Retinal oedema
    Retinal tear
    Sensation of foreign body in eye
    Visual disturbances
    Visual field defects
    Vitreous detachment
    Vitreous haemorrhage


    It is strongly recommended that the UK National Poisons Information Service be consulted on cases of suspected or actual overdose where there is doubt over the degree of risk or about appropriate management.

    The following number will direct the caller to the relevant local centre (0844) 892 0111

    Information may be obtained if you have access to ToxBase the primary clinical toxicology database of the National Poisons Information Service. This is available via password on the internet ( ) or if this is unavailable at the backup site ( ).

    Further Information

    Last Full Review Date: July 2021

    Reference Sources

    Drugs in Pregnancy and Lactation: A Reference Guide to Fetal and Neonatal Risk, 10th edition (2015) ed. Briggs, G., Freeman, R. Wolters Kluwer Health, Philadelphia.

    Summary of Product Characteristics: Jetrea 0.375mg/0.3ml solution for injection. Inceptua AB. Revised September 2020.

    Access the full UK drug database with a FREE Medscape UK Account
    It takes just a few minutes, and you’ll get unlimited access to information on over 11,000 UK drugs.
    Register for Free

    Already a member? Log in

    Medscape UK | Univadis prescription drug monographs & interactions are based on FDB Multilex Content

    FDB Logo

    FDB Disclaimer : FDB Multilex is intended for the use of healthcare professionals and is provided on the basis that the healthcare professionals will retain FULL and SOLE responsibility for deciding what treatment to prescribe or dispense for any particular patient or circumstance.